Cubist’s Feverish Weekend: Rapid Response To Friday’s Cubicin “Approvable” Letter
Firm says its March 27 response to FDA clears up labeling issues related to infective endocarditis indication for daptomycin.
Firm says its March 27 response to FDA clears up labeling issues related to infective endocarditis indication for daptomycin.